- Home
- SLS vs KALV Comparison
SLS vs KALV Comparison
Compare SLS & KALV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SLS | KALV |
|---|---|---|
| Founded | 2012 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 706.7M | 757.7M |
| IPO Year | 2007 | 2014 |
Fundamental Metrics
Financial Performance| Metric | SLS | KALV |
|---|---|---|
| Price | $5.92 | $17.40 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 5 |
| Target Price | $7.00 | ★ $30.00 |
| AVG Volume (30 Days) | ★ 5.5M | 554.3K |
| Earning Date | 04-16-2026 | 04-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 62.69 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $50,000,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 495.66 |
| 52 Week Low | $0.95 | $9.83 |
| 52 Week High | $5.66 | $19.00 |
Technical Indicators
Market Signals| Indicator | SLS | KALV |
|---|---|---|
| Relative Strength Index (RSI) | 74.63 | 66.30 |
| Support Level | $1.48 | $14.45 |
| Resistance Level | N/A | $19.00 |
| Average True Range (ATR) | 0.50 | 0.72 |
| MACD | 0.13 | 0.14 |
| Stochastic Oscillator | 93.19 | 78.38 |
Price Performance
Historical ComparisonAbout SLS SELLAS Life Sciences Group Inc.
SELLAS Life Sciences Group Inc is a late-stage clinical biopharmaceutical company focused on the development of novel therapeutics for a broad range of cancer indications. The company's product candidates currently include galinpepimut-S, or GPS, a peptide immunotherapy directed against the Wilms tumor 1, or WT1, antigen, and GFH009, a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor.
About KALV KalVista Pharmaceuticals Inc.
KalVista Pharmaceuticals Inc is a pharmaceutical company developing and delivering oral therapies for individuals affected by rare diseases with unmet needs. The company applies its knowledge in the kallikrein-kinin system (KKS) and oral drug discovery to develop small-molecule protease inhibitor medicines to address the needs of patients with diseases driven by plasma kallikrein and Factor XIIa. Its FDA-approved product EKTERLY (sebetralstat) is a novel, orally delivered, small-molecule plasma kallikrein inhibitor for the treatment of acute attacks of hereditary angioedema (HAE) in adult and pediatric patients aged twelve years and older.